Precision Medicine: Despite Gains, Optimum Use Far From Reached
Progress has been made in areas such as lung and breast cancer, but panelists at a recent conference noted there are many efficiencies yet to be realized in drug development and reimbursement.
You may also be interested in...
Biomarkers for psychiatric disorders are lacking, but Astellas is investing in its own and external efforts to identify drug targets as well as patients who'll respond to new therapies.
Center for Drug Evaluation and Research Director Janet Woodcock continues to promote innovation in clinical trial design with a review of master protocols in the New England Journal of Medicine.
I-SPY2 study shows promising efficacy for PD-1 inhibitor Keytruda in combination with chemo in high-risk breast cancer – including a tripling of response rate in triple-negative breast cancer – but also raises red flag on immune-mediated adverse events in early-stage patients.